- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
A Multidisciplinary Approach to Managing Complexities in Cancer Care
As September marks National Ovarian Cancer Awareness Month, we sat down with ovarian cancer survivor Marion Roth and Vaagn Andikyan, MD, gynecologic oncologist, Western Connecticut Health Network, to discuss Marion's cancer journey and the importance of a multidisciplinary care team in treating complexities in cancer care.
In 2016, 56-year-old Marion Roth was diagnosed with a rare type of ovarian cancer. She had also been living with type 1 diabetes for nearly 48 years, bringing further complication to her diagnosis and a need for a multidisciplinary team to treat her. Throughout her cancer treatment, Marion was under the care of Vaagn Andikyan, MD, gynecologic oncologist, Western Connecticut Health Network, and Kevin Jain, MD, medical oncologist, Danbury Hospital, as well as Robert Savino, DO, endocrinologist, Western Connecticut Medical Group. Together, the multidisciplinary team collaborated to develop an effective and safe plan to treat Marion's cancer while also maintaining her diabetes treatment.
As September marks National Ovarian Cancer Awareness Month, we sat down with Marion and Dr Andikyan to discuss Marion's cancer journey and the importance of a multidisciplinary care team in treating complexities in cancer care.
To listen to the podcast, please login.
Listen above or or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Learn more about multidisciplinary cancer care, as well as management challenges and treatment options in ovarian cancer:
Dr Mark Soberman on the Next Generation Multidisciplinary Cancer Care Team
Dr Matthew Gubens: Multidisciplinary Approach Can Help Oncologists Tackle Immunotherapy Toxicities
Management Challenges in Ovarian Cancer
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
